Research Paper Volume 12, Issue 8 pp 6570—6585

Figure 3. MALAT1 competitively binds to miR-150-5p, thereby upregulating the expression of miR-150-5p-targeted ICAM-1. (A) Binding sites between miR-150-5p and ICAM-1 predicted using the starBase website. (B) Expression of ICAM-1 in peripheral blood samples of healthy controls (n = 46) and patients with ARDS (n = 46) determined by RT-qPCR. * p < 0.05 vs. peripheral blood samples of healthy controls. (C) Expression of ICAM-1, MALAT1 and miR-150-5p in normal HPMECs and LPS-treated HPMECs determined by RT-qPCR. * p < 0.05 vs. the control. (D) The targeting relationship between miR-150-5p and MALAT1 in cells verified by dual luciferase reporter assay. * p < 0.05 vs. cells transfected with NC. (E) Expression of ICAM-1 in HPMECs determined by RT-qPCR. (F) Expression of ICAM-1 in HPMECs determined by Western blot analysis. * p < 0.05 vs. cells transfected with oe-MALAT1 NC, sh-NC, miR-150-5p mimic NC, or miR-150-5p mimic + oe-MALAT1 NC. The data were measurement data and expressed as mean ± standard deviation. The data between two groups were compared using unpaired t-test and those among multiple groups were analyzed by one-way ANOVA, with Tukey's post hoc test. The cell experiment was repeated three times independently.